367 related articles for article (PubMed ID: 31113236)
1. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea use among children with sickle cell anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
[TBL] [Abstract][Full Text] [Related]
3. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
4. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
[TBL] [Abstract][Full Text] [Related]
5. Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia.
Reeves SL; Dombkowski KJ; Peng HK; Phan H; Kolenic G; Creary SE; Madden B; Lisabeth LD
Pediatr Blood Cancer; 2023 Jul; 70(7):e30332. PubMed ID: 37046404
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Sickle Cell Anemia and Mental Health Diagnoses on Healthcare Use and Preventive Care among Children Enrolled in Medicaid, 2005-2012.
Gondhi JP; Dombkowski KJ; Scott EL; Reeves SL
J Pediatr; 2020 Sep; 224():79-86.e2. PubMed ID: 32446724
[TBL] [Abstract][Full Text] [Related]
7. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
8. High hydroxyurea usage in sickle cell anemia regardless of patient demographics.
Phan V; Park JA; Dulman R; Lewis A; Briere N; Notarangelo B; Yang E
Pediatr Blood Cancer; 2024 Feb; 71(2):e30728. PubMed ID: 38069808
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.
Wang WC; Oyeku SO; Luo Z; Boulet SL; Miller ST; Casella JF; Fish B; Thompson BW; Grosse SD;
Pediatrics; 2013 Oct; 132(4):677-83. PubMed ID: 23999955
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State.
Anders DG; Tang F; Ledneva T; Caggana M; Green NS; Wang Y; Sturman LS
Am J Prev Med; 2016 Jul; 51(1 Suppl 1):S31-8. PubMed ID: 27320463
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
Quarmyne MO; Dong W; Theodore R; Anand S; Barry V; Adisa O; Buchanan ID; Bost J; Brown RC; Joiner CH; Lane PA
Am J Hematol; 2017 Jan; 92(1):77-81. PubMed ID: 27761932
[TBL] [Abstract][Full Text] [Related]
12. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
[TBL] [Abstract][Full Text] [Related]
13. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Lanzkron S; Haywood C; Fagan PJ; Rand CS
J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
[TBL] [Abstract][Full Text] [Related]
14. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
[TBL] [Abstract][Full Text] [Related]
15. Transcranial Doppler Screening Among Children and Adolescents With Sickle Cell Anemia.
Reeves SL; Madden B; Freed GL; Dombkowski KJ
JAMA Pediatr; 2016 Jun; 170(6):550-6. PubMed ID: 27064406
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
Ritho J; Liu H; Hartzema AG; Lottenberg R
Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
[No Abstract] [Full Text] [Related]
17. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
[No Abstract] [Full Text] [Related]
18. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and acceptance of hydroxyurea in the treatment of severe forms of sickle cell disease: a prospective study of 65 cases].
Mellouli F; Chouaibi S; Dhouib N; Ouederni M; Ben Khaled M; Abbes S; Bejaoui M
Tunis Med; 2013; 91(8-9):544-50. PubMed ID: 24227514
[TBL] [Abstract][Full Text] [Related]
20. Changes in Hydroxyurea Use Among Youths Enrolled in Medicaid With Sickle Cell Anemia After 2014 Revision of Clinical Guidelines.
Reeves SL; Peng HK; Wing JJ; Cogan LW; Goel A; Anders D; Green NS; Lisabeth LD; Dombkowski KJ
JAMA Netw Open; 2023 Mar; 6(3):e234584. PubMed ID: 36961463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
